Products from BPS Bioscience require a minimum order value above 400€
Background: Quisinostat, also known asJNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.
Biological Activity: JNJ-26481585 inhibits HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11 with IC50 values of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM, respectively.
CAS Number: 875320-29-9
Description: JNJ-26481585, also known as Quisinostat, is a potent pan-HDAC inhibitor. JNJ-26481585 induces histone acetylationand inhibits cancer cell proliferation.
Purity: ≥98% by HPLC
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: Rajak, H., et al. Curr Med Chem. 2014;21(23):2642-64.
English
Deutsch
